Cell Signaling Technology, Inc. (CST) announced today a third agreement with AstraZeneca under which it will continue to perform CST's PhosphoScan technology to identify phosphorylation profiles
and prospective biomarkers of kinase targeted lead compounds. CST's PhosphoScan
proteomics technology is a patent-pending strategy that enables the discovery
of drug target phospho-profiles in cells and disease tissues.